Heart failure medicine LCZ696 to be available to the NHS
2 September 2015 | By Victoria White
Heart failure treatment LCZ696 (sacubitril valsartan) has been given a positive scientific opinion under the MHRA Early Access to Medicines Scheme...
List view / Grid view
News
NICE draft guidance conditionally recommends Vimizim
2 September 2015 | By Victoria White
NICE has provisionally recommended BioMarin’s Vimizim for the treatment of the very rare inherited lysosomal storage disease, mucopolysaccharidosis type IVa...
BMS gets exclusive rights to acquire Promedior
2 September 2015 | By Victoria White
As well as granting exclusive rights to acquire Promedior, the agreement grants Bristol-Myers Squibb worldwide rights to Promedior's lead asset PRM-151.
FDA grants priority review for Empliciti Biologics License Application
2 September 2015 | By Victoria White
The FDA has accepted for priority review the BLA for Empliciti (elotuzumab) for the treatment of multiple myeloma as combination therapy...
TECOS analysis adds heart failure data for sitagliptin
2 September 2015 | By Victoria White
New TECOS study findings have shown that patients with type-2 diabetes can safely take sitagliptin without an increased risk of cardiovascular complications...
New technology allows unattended sampling and synthesis of chemical reactions
1 September 2015 | By Mettler Toledo
The new EasySampler Connectivity Kit enables integration of EasySampler and the associated sampling information with the touchscreen of METTLER TOLEDO Reactor Systems for Chemical Synthesis and Automated Jacketed Lab Reactor Control. EasySampler data is automatically transferred to, and reported with, the referring experiment to enable unattended sampling and synthesis of…
Sartorius Stedim Biotech and GE Healthcare sign worldwide OEM supply agreement
Sartorius Stedim Biotech, a leading international supplier for the biopharmaceutical industries and GE Healthcare’s Life Sciences business, a provider of start-to-finish enterprise solutions, technologies and services for biopharmaceutical manufacturing, today announced they have entered into a worldwide OEM supply agreement for Sartorius Stedim Biotech’s innovative membrane adsorber purification technology, Sartobind™.
ESC launches new concept for driving innovation in cardiovascular research with exclusive support from Boehringer Ingelheim
1 September 2015 | By Charlotte Batchelor
Four grants will be awarded to independent research projects, focused on improving patient outcomes in thromboembolic diseases
Sticky honey helps icky acne
1 September 2015 | By Charlotte Batchelor
Large clinical trial shows that a New Zealand kanuka honey formulation helps acne...
European marketing authorisation granted for Alexion’s Kanuma™ (sebelipase alfa)
1 September 2015 | By Nick Jackson
Alexion Pharmaceuticals, Inc. has announced that the European Commission has approved Kanuma™ (sebelipase alfa) for long-term enzyme replacement therapy in patients of all ages with lysosomal acid lipase deficiency...
Abbott announces positive results of its naturally dissolving stent from ABSORB Japan study
1 September 2015 | By Nick Jackson
Abbott has announced positive one-year clinical results from ABSORB Japan, a multi-center, randomised trial comparing the safety and effectiveness of Abbott's fully dissolving AbsorbTM heart stent to XIENCE®...
First patient recruited in Pollinex Quattro Birch dose ranging study in Germany and Austria
1 September 2015 | By Nick Jackson
As a precursor to the Phase III trial, this Phase IIb study will select the optimum dose, and is being conducted in Germany under the Therapy Allergens Ordinance (Therapieallergene-Verordnung)...
Mylan shareholders approve proposed acquisition of Perrigo
28 August 2015 | By Victoria White
Mylan's proposed acquisition of Perrigo received the approval of two-thirds of the votes cast by Mylan shareholders at an extraordinary general meeting...
FDA approves LDL cholesterol drug Repatha
28 August 2015 | By Victoria White
Repatha, the second drug approved in a new class of drugs known as PCSK9 inhibitors, has been approved by the FDA for some patients who are unable to get their LDL cholesterol under control with current treatment options...
Novartis donates $40 million of treatments to treat leprosy
28 August 2015 | By Victoria White
Novartis has renewed its pledge with the World Health Organisation (WHO) to work to end leprosy by extending its donation of multidrug therapy medicines...
